FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319461346> ?p ?o ?g. }

• W4319461346 endingPage "1568" @default.
• W4319461346 startingPage "1557" @default.
• W4319461346 abstract "In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to reverse this resistance. Non-luminal breast cancer subtype and high levels of CCNE1 are candidate biomarkers in this setting, but further validation is needed.We performed mRNA gene expression profiling and correlation with progression-free survival (PFS) on 455 tumor samples included in the phase III PEARL study, which assigned patients with HR+/HER2- MBC to receive palbociclib+endocrine therapy (ET) versus capecitabine. Estrogen receptor-positive (ER+)/HER2- breast cancer cell lines were used to generate and characterize resistance to palbociclib+ET.Non-luminal subtype was more prevalent in metastatic (14%) than in primary tumor samples (4%). Patients with non-luminal tumors had median PFS of 2.4 months with palbociclib+ET and 9.3 months with capecitabine; HR 4.16, adjusted P value < 0.0001. Tumors with high CCNE1 expression (above median) also had worse median PFS with palbociclib+ET (6.2 months) than with capecitabine (9.3 months); HR 1.55, adjusted P value = 0.0036. In patients refractory to palbociclib+ET (PFS in the lower quartile), we found higher levels of Polo-like kinase 1 (PLK1). In an independent data set (PALOMA3), tumors with high PLK1 show worse median PFS than those with low PLK1 expression under palbociclib+ET treatment. In ER+/HER2- cell line models, we show that PLK1 inhibition reverses resistance to palbociclib+ET.We confirm the association of non-luminal subtype and CCNE1 with resistance to CDK4/6i+ET in HR+ MBC. High levels of PLK1 mRNA identify patients with poor response to palbociclib, suggesting PLK1 could also play a role in the setting of resistance to CDK4/6i." @default.
• W4319461346 created "2023-02-09" @default.
• W4319461346 creator A5000049294 @default.
• W4319461346 creator A5002562175 @default.
• W4319461346 creator A5002930240 @default.
• W4319461346 creator A5005632793 @default.
• W4319461346 creator A5016401289 @default.
• W4319461346 creator A5018922989 @default.
• W4319461346 creator A5025502055 @default.
• W4319461346 creator A5032118433 @default.
• W4319461346 creator A5032379353 @default.
• W4319461346 creator A5038507025 @default.
• W4319461346 creator A5040413764 @default.
• W4319461346 creator A5042829808 @default.
• W4319461346 creator A5043393829 @default.
• W4319461346 creator A5051072215 @default.
• W4319461346 creator A5058112962 @default.
• W4319461346 creator A5060044961 @default.
• W4319461346 creator A5061258329 @default.
• W4319461346 creator A5069572905 @default.
• W4319461346 creator A5075937719 @default.
• W4319461346 creator A5076792937 @default.
• W4319461346 creator A5077805370 @default.
• W4319461346 creator A5077961608 @default.
• W4319461346 creator A5081820273 @default.
• W4319461346 date "2023-02-07" @default.
• W4319461346 modified "2023-10-06" @default.
• W4319461346 title "<i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer" @default.
• W4319461346 cites W1464936406 @default.
• W4319461346 cites W2025332148 @default.
• W4319461346 cites W2096439168 @default.
• W4319461346 cites W2130410032 @default.
• W4319461346 cites W2141717219 @default.
• W4319461346 cites W2167831982 @default.
• W4319461346 cites W2467902526 @default.
• W4319461346 cites W2513942179 @default.
• W4319461346 cites W2592406193 @default.
• W4319461346 cites W2620993107 @default.
• W4319461346 cites W2805575723 @default.
• W4319461346 cites W2808503488 @default.
• W4319461346 cites W2917464640 @default.
• W4319461346 cites W2925017918 @default.
• W4319461346 cites W2974027076 @default.
• W4319461346 cites W2981209325 @default.
• W4319461346 cites W2995593755 @default.
• W4319461346 cites W3048840742 @default.
• W4319461346 cites W3091902443 @default.
• W4319461346 cites W3115380088 @default.
• W4319461346 cites W3136964832 @default.
• W4319461346 cites W3176308859 @default.
• W4319461346 cites W4281842244 @default.
• W4319461346 cites W4293795388 @default.
• W4319461346 doi "https://doi.org/10.1158/1078-0432.ccr-22-2206" @default.
• W4319461346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36749874" @default.
• W4319461346 hasPublicationYear "2023" @default.
• W4319461346 type Work @default.
• W4319461346 citedByCount "2" @default.
• W4319461346 countsByYear W43194613462023 @default.
• W4319461346 crossrefType "journal-article" @default.
• W4319461346 hasAuthorship W4319461346A5000049294 @default.
• W4319461346 hasAuthorship W4319461346A5002562175 @default.
• W4319461346 hasAuthorship W4319461346A5002930240 @default.
• W4319461346 hasAuthorship W4319461346A5005632793 @default.
• W4319461346 hasAuthorship W4319461346A5016401289 @default.
• W4319461346 hasAuthorship W4319461346A5018922989 @default.
• W4319461346 hasAuthorship W4319461346A5025502055 @default.
• W4319461346 hasAuthorship W4319461346A5032118433 @default.
• W4319461346 hasAuthorship W4319461346A5032379353 @default.
• W4319461346 hasAuthorship W4319461346A5038507025 @default.
• W4319461346 hasAuthorship W4319461346A5040413764 @default.
• W4319461346 hasAuthorship W4319461346A5042829808 @default.
• W4319461346 hasAuthorship W4319461346A5043393829 @default.
• W4319461346 hasAuthorship W4319461346A5051072215 @default.
• W4319461346 hasAuthorship W4319461346A5058112962 @default.
• W4319461346 hasAuthorship W4319461346A5060044961 @default.
• W4319461346 hasAuthorship W4319461346A5061258329 @default.
• W4319461346 hasAuthorship W4319461346A5069572905 @default.
• W4319461346 hasAuthorship W4319461346A5075937719 @default.
• W4319461346 hasAuthorship W4319461346A5076792937 @default.
• W4319461346 hasAuthorship W4319461346A5077805370 @default.
• W4319461346 hasAuthorship W4319461346A5077961608 @default.
• W4319461346 hasAuthorship W4319461346A5081820273 @default.
• W4319461346 hasBestOaLocation W43194613461 @default.
• W4319461346 hasConcept C121608353 @default.
• W4319461346 hasConcept C126322002 @default.
• W4319461346 hasConcept C143998085 @default.
• W4319461346 hasConcept C2775930923 @default.
• W4319461346 hasConcept C2777909004 @default.
• W4319461346 hasConcept C2779744173 @default.
• W4319461346 hasConcept C502942594 @default.
• W4319461346 hasConcept C526805850 @default.
• W4319461346 hasConcept C530470458 @default.
• W4319461346 hasConcept C71924100 @default.
• W4319461346 hasConceptScore W4319461346C121608353 @default.
• W4319461346 hasConceptScore W4319461346C126322002 @default.
• W4319461346 hasConceptScore W4319461346C143998085 @default.
• W4319461346 hasConceptScore W4319461346C2775930923 @default.
• W4319461346 hasConceptScore W4319461346C2777909004 @default.

• next